Barclays PLC Acquires 35,832 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Barclays PLC raised its holdings in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 303.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,655 shares of the biopharmaceutical company’s stock after acquiring an additional 35,832 shares during the quarter. Barclays PLC owned about 0.14% of Achieve Life Sciences worth $226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock valued at $3,552,000 after purchasing an additional 48,474 shares in the last quarter. State Street Corp grew its position in shares of Achieve Life Sciences by 6.8% during the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after purchasing an additional 27,419 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Achieve Life Sciences by 134.2% during the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 14,360 shares in the last quarter. MetLife Investment Management LLC grew its position in Achieve Life Sciences by 65.6% in the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,939 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in Achieve Life Sciences in the second quarter worth $69,000. Institutional investors own 33.52% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ACHV. Rodman & Renshaw began coverage on shares of Achieve Life Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $12.00 target price for the company. Raymond James initiated coverage on shares of Achieve Life Sciences in a research report on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 target price for the company. Finally, RODMAN&RENSHAW upgraded shares of Achieve Life Sciences to a “strong-buy” rating in a research report on Thursday, November 14th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $14.80.

Achieve Life Sciences Trading Down 7.8 %

Shares of ACHV stock opened at $2.85 on Wednesday. Achieve Life Sciences, Inc. has a 12-month low of $2.84 and a 12-month high of $5.59. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The firm’s 50 day moving average is $3.94 and its 200 day moving average is $4.42. The stock has a market capitalization of $98.01 million, a P/E ratio of -2.52 and a beta of 1.66.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same quarter in the previous year, the company posted ($0.34) EPS. Research analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.